1.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Lexicon Pharmaceuticals to advance obesity treatment with new ACSL5 inhibitor data - Traders Union
Novo Nordisk (NVO) Collaborates with Lexicon on Obesity Treatmen - GuruFocus
Lexicon Pharmaceuticals Publishes Preclinical Data Supporting ACSL5 as Target for Obesity Treatment - Quiver Quantitative
Lexicon Pharmaceuticals (Nasdaq: LXRX) publishes ACSL5 obesity data supporting LX9851 - Stock Titan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Clinical data on effect of sotagliflozin on adipose distribution in non-diabetic patients - marketscreener.com
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum - The Manila Times
Clinical Data On Effect Of Sotagliflozin On Adipose Distribution In Non-Diabetic Patients - TradingView
Lexicon Pharmaceuticals to Present Clinical Data on Sotagliflozin at CVCT 2025 Conference - Quiver Quantitative
Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development - MSN
Is Lexicon Pharmaceuticals Inc. stock attractive for ETFs2025 Key Highlights & Daily Profit Maximizing Trade Tips - Newser
Year in Review: Local co. striking deal worth up to $1B with Ozempic maker was a Deal of the Week - The Business Journals
Carcinoid Syndrome Market to Expand Significantly by 2034, - openPR.com
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well - Seeking Alpha
Piper Sandler Healthcare Conference - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Will Lexicon Pharmaceuticals Inc. stock deliver long term returns2025 Market Overview & Fast Entry High Yield Stock Tips - moha.gov.vn
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences - The Manila Times
Lexicon Pharma (Nasdaq: LXRX) in Piper Sandler 37th and Evercore 8th investor events - Stock Titan
Would You Still Hold Lexicon Pharmaceuticals Stock If It Fell 30%? - Trefis
10 Fastest Growing Penny Stocks to Buy Now - Insider Monkey
Why Lexicon Pharmaceuticals Inc. stock is considered a top pick2025 Stock Rankings & Daily Market Momentum Tracking - newser.com
Can Lexicon Pharmaceuticals Inc. stock deliver consistent earnings growthWeekly Trend Recap & Reliable Intraday Trade Plans - newser.com
Will Lexicon Pharmaceuticals Inc. stock split attract more investorsBear Alert & Daily Price Action Insights - newser.com
Can Lexicon Pharmaceuticals Inc. stock resist market sell offs2025 Institutional Moves & Weekly Watchlist for Hot Stocks - newser.com
Can Lexicon Pharmaceuticals Inc. stock surprise with earnings upsideQuarterly Market Review & Accurate Buy Signal Notifications - newser.com
Transcript : Lexicon Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 05 - MarketScreener
Is Lexicon Pharmaceuticals Inc. stock attractive for growth ETFs2025 Earnings Surprises & Verified Technical Trade Signals - newser.com
How to manage a losing position in Lexicon Pharmaceuticals Inc.Analyst Upgrade & Verified Entry Point Signals - newser.com
Lexicon Pharmaceuticals at Jefferies London: Strategic Pipeline Progress By Investing.com - Investing.com Canada
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Published on: 2025-11-16 06:10:48 - newser.com
Wall Street Zen Downgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Hold - MarketBeat
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals backs Type 1 diabetes research ahead of World Diabetes Day - Traders Union
What the charts say about Lexicon Pharmaceuticals Inc. todayTake Profit & Real-Time Chart Breakout Alerts - newser.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):